Promising combo therapy for aggressive prostate cancer tested before surgery

This study tested whether giving a targeted radiation drug (LuPSMA) with or without an immunotherapy drug (ipilimumab) before prostate removal surgery is safe and feasible for men with very high-risk prostate cancer. Only one participant was enrolled before the study was stopped early. The main goals were to see if surgery could happen on time and if the treatment led to complete cancer disappearance in the removed prostate.